[A21-136] Sofosbuvir/ velpatasvir/ voxilaprevir (hepatitis C, 12 to <18 years of age) - Benefit assessment according to §35a Social Code Book V

Last updated 17.01.2022

Project no.:

Commission awarded on 15.10.2021 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Immune system and infections


Chronic hepatitis C in adolescents aged 12 to < 18 years

Result of dossier assessment:
  • Genotype 1, 4, 5 or 6: added benefit not proven.
  • Genotype 2 or 3: added benefit not proven.

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form